Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Recbio Technology CoFRA:G93 24 EV-to-FCF is -5.55 as of Aug. 25, 2026. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 321 Biotechnology companies, Jiangsu Recbio Technology Co ranks worse than 311526.17% on this metric.
The historical rank and industry rank for Jiangsu Recbio Technology Co's EV-to-FCF or its related term are showing as below:
FRA:G93'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.59 Med: -4.39 Max: -3.31
Current: -5.59
During the past 7 years, the highest EV-to-FCF of Jiangsu Recbio Technology Co was -3.31. The lowest was -5.59. And the median was -4.39.
FRA:G93's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 18.66
vs FRA:G93: -5.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Recbio Technology Co (FRA:G93) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Recbio Technology Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Recbio Technology Co's share price for today is €0.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jiangsu Recbio Technology Co EV-to-FCF Related Terms
Jiangsu Recbio Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's EV-to-FCF falls into.
Jiangsu Recbio Technology Co's current Enterprise Value is €403.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-72.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co (FRA:G93) has a EV-to-FCF of -5.55 as of Aug. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Recbio Technology Co and its competitors. According to the industry distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 321 companies in the Biotechnology industry.
Is Jiangsu Recbio Technology Co's EV-to-FCF too high?
Jiangsu Recbio Technology Co's current EV-to-FCF is -5.55. Based on the distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 321 companies for EV-to-FCF. This places Jiangsu Recbio Technology Co in the lower half of its industry. The industry median EV-to-FCF is 18.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.66, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Recbio Technology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Recbio Technology Co's current EV-to-FCF is -5.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current EV-to-FCF of -5.55. The current EV-to-FCF is -5.55. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current EV-to-FCF is -5.55 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score
Get the complete analysis for FRA:G93
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G93 has been successfully added to your 
